BioXcel Therapeutics, Inc. (BTAI)
Largest Insider Buys in Sector
BTAI Stock Price History Chart
BTAI Stock Performance
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the …
Insider Activity of BioXcel Therapeutics, Inc.
Over the last 12 months, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $457,050 worth of BioXcel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $34.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,108 shares for transaction amount of $14,514 was made by MUELLER PETER (director) on 2019‑08‑23.
List of Insider Buy and Sell Transactions, BioXcel Therapeutics, Inc.
| 2024-12-16 | Sale | CEO and President | 3,117 0.0062% | $0.36 | $1,131 | -14.76% | ||
| 2024-12-16 | Sale | Chief Scientific Officer | 430 0.0008% | $0.35 | $152 | -14.76% | ||
| 2024-12-16 | Sale | Chief Financial Officer | 577 0.0011% | $0.36 | $207 | -14.76% | ||
| 2024-12-16 | Sale | See Remarks | 165 0.0003% | $0.35 | $58 | -14.76% | ||
| 2024-10-03 | Sale | Chief Scientific Officer | 7,175 0.0181% | $0.55 | $3,946 | -1.40% | ||
| 2024-10-03 | Sale | See Remarks | 6,863 0.0173% | $0.55 | $3,775 | -1.40% | ||
| 2024-10-03 | Sale | Chief Financial Officer | 7,175 0.0181% | $0.55 | $3,946 | -1.40% | ||
| 2024-10-03 | Sale | See Remarks | 5,556 0.014% | $0.55 | $3,056 | -1.40% | ||
| 2024-10-03 | Sale | Chief Commercial Officer | 6,272 0.0158% | $0.55 | $3,450 | -1.40% | ||
| 2024-09-16 | Sale | CEO and President | 1,982 0.0052% | $0.69 | $1,367 | -13.25% | ||
| 2024-09-16 | Sale | Chief Scientific Officer | 355 0.0009% | $0.69 | $245 | -13.25% | ||
| 2024-09-16 | Sale | See Remarks | 345 0.0009% | $0.69 | $238 | -13.25% | ||
| 2024-09-16 | Sale | Chief Financial Officer | 356 0.0009% | $0.69 | $246 | -13.25% | ||
| 2024-09-16 | Sale | Chief Commercial Officer | 215 0.0006% | $0.69 | $149 | -13.25% | ||
| 2024-09-16 | Sale | See Remarks | 138 0.0004% | $0.69 | $95 | -13.25% | ||
| 2024-06-17 | Sale | CEO and President | 2,134 0.0051% | $1.28 | $2,739 | -53.95% | ||
| 2024-06-17 | Sale | Chief Scientific Officer | 372 0.0009% | $1.28 | $476 | -53.95% | ||
| 2024-06-17 | Sale | See Remarks | 361 0.0008% | $1.26 | $456 | -53.95% | ||
| 2024-06-17 | Sale | Chief Financial Officer | 372 0.0009% | $1.26 | $470 | -53.95% | ||
| 2024-06-17 | Sale | See Remarks | 155 0.0004% | $1.28 | $199 | -53.95% |
Insider Historical Profitability
| Mehta Vimal | CEO and President | 59605 0.1201% | $0.35 | 9 | 12 | +91.12% |
| Yocca Frank | Chief Scientific Officer | 28931 0.0583% | $0.35 | 5 | 10 | +91.88% |
| Steinhart Richard I | Chief Financial Officer | 20932 0.0422% | $0.35 | 3 | 8 | +87.62% |
| MUELLER PETER | director | 168320 0.3392% | $0.35 | 6 | 0 | +104.84% |
| Nandabalan Krishnan | 0 0% | $0.35 | 1 | 5 | +93.45% |
Institutional Investor Ownership
| Fidelity Investments | $7.03M | 6.65 | 2.49M | -0.97% | -$68,943.36 | <0.0001 | |
| BlackRock | $3.75M | 3.54 | 1.33M | -3.36% | -$130,137.36 | <0.0001 | |
| The Vanguard Group | $3.1M | 2.93 | 1.1M | +0.91% | +$27,951.83 | <0.0001 | |
| Ameriprise Financial | $1.63M | 1.54 | 579,164 | +7.04% | +$107,442.03 | <0.0001 | |
| State Street | $1.31M | 1.24 | 464,908 | +5.58% | +$69,304.34 | <0.0001 |